Excessive urination at night, or nocturia, is not uncommon in postmenopausal women. There are a number of treatment options available but with varying degrees of success.
In this clinical practice review correspondence recently published in the Journal of Clinical Endocrine and Metabolism, physicians challenge some of the standard prescribing guidance for gender affirming hormone therapy.
Study authors hypothesized that longer-acting testosterone replacement therapy will have significant impact on suppressing HPG axis compared with short-acting TRT preparations.
Study authors assessed the long-term effectiveness and safety of GH in real-life clinical practice and whether age mattered at the time of treatment initiation.
Researchers set out to summarize clinical outcomes experienced by patients who discontinue thyroid hormone replacement therapy.
The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.
The age at and cause of period cessation were not found to be associated with conventional cardiovascular risk factors across middle age and later life.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
For postmenopausal women, conjugated equine estrogen alone is associated with a long-term decrease in breast cancer incidence, while CEE plus medroxyprogesterone acetate is associated with increased incidence.
